Register entry
- Registered sites
- 1
- Active NDC listings
- 22
- Labeller names
- 3
- Live patents
- 40
- Countries
- 1
- Base
- Switzerland
Authorisation
Registered operations
Analytical testing1Active ingredient (API) manufacture1Finished drug manufacture1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Vifor (International) Inc.Registrant: Vifor (International) AG | Rechenstrasse 37, St. Gallen, 9014, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3002808450482603065 |
Catalogue
Drug listings by form and route
2222 active NDC listings: 20 human prescription drug, 1 bulk ingredient, 1 drug for further processing. By marketing category: BLA 15, NDA 5, BULK INGREDIENT 1, DRUG FOR FURTHER PROCESSING 1.
| Dosage form | NDCs |
|---|---|
| injection, solution | 16 |
| powder, for suspension | 4 |
| liquid | 1 |
| powder | 1 |
| Route | NDCs |
|---|---|
| intravenous | 16 |
| subcutaneous | 6 |
| oral | 4 |
| Labeller name on the listing | NDCs |
|---|---|
| vifor (international) inc. | 17 |
| vifor pharma, inc. | 4 |
| vifor (international), inc. | 1 |
Exclusivity
Patents and exclusivities
40| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8216560 | VELTASSApatiromer sorbitex calcium | use | Mar 2027 |
| 8282913 | VELTASSApatiromer sorbitex calcium | product | May 2027 |
| 10017536 | KORSUVAdifelikefalin acetate | substance | Nov 2027 |
| 10138270 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 10793596 | KORSUVAdifelikefalin acetate | substance, product | Nov 2027 |
| 7713937 | KORSUVAdifelikefalin acetate | substance, product | Nov 2027 |
| 7727963 | KORSUVAdifelikefalin acetate | substance, product | Nov 2027 |
| 8217007 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 8236766 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 8486894 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 8536131 | KORSUVAdifelikefalin acetate | substance, product | Nov 2027 |
| 9334305 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 9359399 | KORSUVAdifelikefalin acetate | use | Nov 2027 |
| 8147873 | VELTASSApatiromer sorbitex calcium | product | Jun 2028 |
| 8337824 | VELTASSApatiromer sorbitex calcium | substance | May 2030 |
| 7402564 | KORSUVAdifelikefalin acetate | substance, product | Nov 2032 |
| 11123363 | VELTASSApatiromer sorbitex calcium | use | Oct 2033 |
| 9492476 | VELTASSApatiromer sorbitex calcium | use | Oct 2033 |
| 9925212 | VELTASSApatiromer sorbitex calcium | use | Oct 2033 |
Catalogue
Marketed products
22| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Ferric Carboxymaltose | powder | 59353-363BULK INGREDIENT |
| - | Iron Sucrose | liquid | 59353-652DRUG FOR FURTHER PROCESSING |
| Korsuva | difelikefalin | injection, solution, intravenous | 59353-065NDA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-400BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-401BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-402BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-403BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-404BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-405BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-406BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-407BLA |
| Mircera | Methoxy polyethylene glycol-epoetin beta | injection, solution, intravenous | 59353-408BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-002BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-003BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-004BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-010BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-120BLA |
| RETACRIT | epoetin alfa-epbx | injection, solution, intravenous, subcutaneous | 59353-220BLA |
| VELTASSA | patiromer | powder, for suspension, oral | 53436-010NDA |
| VELTASSA | patiromer | powder, for suspension, oral | 53436-084NDA |
| VELTASSA | patiromer | powder, for suspension, oral | 53436-168NDA |
| VELTASSA | patiromer | powder, for suspension, oral | 53436-252NDA |
Compare
Comparable companies in Switzerland
- Herbamed AG1 site · 173 NDC
- Ricola Ag1 site · 84 NDC
- Avyxa GmbH1 site · 29 NDC
- Bachem AG1 site · 23 NDC
- DOTTIKON EXCLUSIVE SYNTHESIS AG1 site · 16 NDC
- HAS Healthcare Advanced Synthesis SA1 site · 11 NDC
- Cerbios-Pharma SA1 site · 9 NDC
- SINTETICA S.A.1 site · 9 NDC
- Similasan AG1 site · 7 NDC
- Swiss Caps AG1 site · 6 NDC
Enquiry
Common questions
- Is Vifor (International) AG FDA approved?
- Vifor (International) AG holds 1 FDA-registered establishment in Switzerland. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Vifor (International) AG's drugs manufactured?
- The FDA register lists St. Gallen. Registered operations: analytical testing, active ingredient (API) manufacture, finished drug manufacture.
- What drugs does Vifor (International) AG make?
- 22 products are listed under Vifor (International) AG in the openFDA NDC Directory, most often as injection, solution; powder, for suspension; liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.